Trexquant Investment LP Has $17.77 Million Stock Position in Insulet Co. (NASDAQ:PODD)

Trexquant Investment LP grew its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 25.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 68,045 shares of the medical instruments supplier's stock after purchasing an additional 13,996 shares during the period. Trexquant Investment LP owned about 0.10% of Insulet worth $17,765,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Norges Bank acquired a new position in Insulet during the 4th quarter valued at about $248,806,000. Raymond James Financial Inc. purchased a new stake in Insulet during the 4th quarter worth approximately $69,433,000. Alecta Tjanstepension Omsesidigt acquired a new position in Insulet during the 4th quarter valued at approximately $53,184,000. Artisan Partners Limited Partnership lifted its stake in shares of Insulet by 24.1% during the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after buying an additional 149,524 shares during the period. Finally, Proficio Capital Partners LLC acquired a new position in shares of Insulet in the 4th quarter valued at $28,422,000.

Insulet Stock Down 4.5 %

PODD traded down $11.54 during midday trading on Friday, hitting $245.26. 1,337,197 shares of the company's stock traded hands, compared to its average volume of 713,775. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market cap of $17.22 billion, a PE ratio of 42.36, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. Insulet Co. has a one year low of $160.19 and a one year high of $289.46. The stock's fifty day simple moving average is $269.86 and its 200-day simple moving average is $259.70.

Remove Ads

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million during the quarter, compared to analysts' expectations of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, equities analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. This represents a 36.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PODD. JPMorgan Chase & Co. increased their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research note on Thursday, December 12th. Stifel Nicolaus upped their price target on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a report on Friday, February 21st. Wells Fargo & Company lifted their target price on shares of Insulet from $305.00 to $322.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Citigroup raised their price target on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group lifted their target price on shares of Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.